Elevation of dopamine induced by cigarette smoking: Novel insights from a 11 C-(+)-PHNO PET study in humans

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 415-424

  Le Foll, Bernard ^a,b,c   Guranda, Mihail ^a   Wilson, Alan A ^a,c   Houle, Sylvain ^a   Rusjan, Pablo M ^a   Wing, Victoria C ^a   Zawertailo, Laurie ^a,b   Busto, Usoa ^a   Selby, Peter ^a,b,c   Brody, Arthur L ^d   George, Tony P ^a,b,c   Boileau, Isabelle ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dopamine; nicotine; PET; tobacco; ventral tegmental area

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CARBON 11; CARBON MONOXIDE; COTININE; DOPAMINE; NAXAGOLIDE; NICOTINE; RADIOLIGAND;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; BREATH ALCOHOL ANALYZER; CHEMICAL ANALYZER; CLINICAL ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; HUMAN; HYPOTHESIS; MALE; MINNESOTA NICOTINE WITHDRAWAL SCALE; MOOD; MOTIVATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE OF SMOKING URGE; SELF REPORT; SMOKING; SMOKING CESSATION; STATE TRAIT ANXIETY INVENTORY; TOBACCO CRAVING QUESTIONNAIRE; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; CARBON RADIOISOTOPES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D3; SMOKING; UP-REGULATION; YOUNG ADULT;

EID: 84890562058     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.209     Document Type: Article

References (60)

1. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA (2003). Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28: 1272-1280.
2. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004). The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54: 65-71.
3. Beck AT, Steer RA (1997). Beck Depression Inventory. Center for Cognitive Therapy: Philadelphia, PA, USA.
4. Bernert JT Jr., Turner WE, Pirkle JL, Sosnoff CS, Akins JR Waldrep MK et al (1997). Development and validation of sensitive method for determination of serum cotinine in smokers and nonsmokers by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Clin Chem 43: 2281-2291.
5. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J et al (2012). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(\+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353-1359.
6. Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM et al (2013). The D(2/3) dopamine receptor in pathological gambling: a positron emission tomography study with [(11) C]-(\+) propyl-hexahydro-naphtho-oxazin and [(11) C]raclopride. Addiction 108: 953-963.
7. Brody AL, London ED, Olmstead RE, Allen-Martinez Z, Shulenberger S, Costello MR et al (2010). Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for tobacco dependence. Psychiatry Res 183: 218-224.
8. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z Scheibal D, Abrams AL et al (2009). Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 34: 282-289.
9. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E Shiraga S et al (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
10. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH Grossman P et al (2004). Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161: 1211-1218.
11. Chiuccariello L, Boileau I, Guranda M, Rusjan PM, Wilson AA Zawertailo L et al (2013). Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: a [(11)C]-(\+)-PHNO PET study. PLoS One 8: e60382.
12. Cumming P, Rosa-Neto P,Watanabe H, Smith D, Bender D, Clarke PB et al (2003). Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage 19: 1127-1136.
13. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274.
14. Domino EF, Evans CL, Ni L, Guthrie SK, Koeppe RA, Zubieta JK (2012). Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 38: 236-240.
15. Domino EF, Ni L, Domino JS, Yang W, Evans C, Guthrie S et al (2013). Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine. Nicotine Tob Res 15: 11-21.
16. Domino EF, Tsukada H (2009). Nicotine sensitization of monkey striatal dopamine release. Eur J Pharmacol 607: 91-95.
17. Forget B, Hamon M, Thiebot MH (2009). Involvement of alpha1 adrenoceptors in conditioned place preference supported by nicotine in rats. Psychopharmacology (Berl) 205: 503-515.
18. Forget B,Wertheim C, Mascia P, Pushparaj A, Goldberg SR, Le Foll B (2010). Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 35: 1751-1760.
19. Frederiksen LW, Miller PM, Peterson GL (1977). Topographical components of smoking behavior. Addict Behav 2: 55-61.
20. Gallezot J-D, Kloczynski T, Weinzimmer D, Labaree D, Zheng M-Q Lim K et al (2013). Imaging nicotine-and amphetamine-induced dopamine release in rhesus monkeys with [11C]PHNO versus [11C]raclopride PET. Neuropsychopharmacology (e-pub ahead of print).
21. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D Singhal T et al (2012). Affinity and selectivity of [(1)(1)C]-(\+) PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66: 489-500.
22. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM Seeman P et al (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(\+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
23. Grieder TE, George O, Tan H, George SR, Le Foll B, Laviolette SR et al (2012). Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc Natl Acad Sci USA 109: 3101-3106.
24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991). The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86: 1119-1127.
25. Heishman SJ, Singleton EG, Moolchan ET (2003). Tobacco craving questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res 5: 645-654.
26. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: 289-294.
27. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL Benowitz NL (2000). Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 66: 553-558.
28. Kemppainen H, Raivio N, Suo-Yrjo V, Kiianmaa K (2012). Opioidergic modulation of ethanol self-administration in the ventral pallidum. Alcohol Clin Exp Res 36: 286-293.
29. Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J et al (2010). The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacology 13: 181-190.
30. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4(3 Pt 1): 153-158.
31. Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-451.
32. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea Ponce Y, Zoghbi SS et al (1995). SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182-1190.
33. Laviolette SR, Van Der Kooy D (2003a). Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 8: 50-59.
34. Laviolette SR, Van Der Kooy D (2003b). The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunitcontaining nicotinic acetylcholine receptor. Psychopharmacology (Berl) 166: 306-313.
35. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P (2009a). Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 20: 1-17.
36. Le Foll B, Goldberg SR (2009b). Effects of nicotine in experimental animals and humans: an update on addictive properties. Handbook of Experimental Pharmacology 192: 335-367.
37. Le Foll B, Goldberg SR, Sokoloff P (2007). Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Invest Drug 16: 45-57.
38. Le Foll B, Schwartz J-C, Sokoloff P (2003). Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol Psychiatry 8: 225-230.
39. Le Foll B, Sokoloff P, Stark H, Goldberg SR (2005). Dopamine D3 ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminativestimulus or antidepressant-like effects. Neuropsychopharmacology 30: 720-730.
40. Lee EM, Malson JL, Waters AJ, Moolchan ET, Pickworth WB (2003). Smoking topography: reliability and validity in dependent smokers. Nicotine Tob Res 5: 673-679.
41. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004). Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29: 259-268.
42. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003a). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamineinduced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285.
43. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003b). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
44. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007). The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse 61: 637-645.
45. Pak AC, Ashby CR Jr., Heidbreder CA, Pilla M, Gilbert J, Xi ZX et al (2006). The selective dopamine D3 receptor antagonist SB 277011A reduces nicotine-enhanced brain reward and nicotinepaired environmental cue functions. Int J Neuropsychopharmacol 9: 585-602.
46. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257.
47. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006a). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79-89.
48. Rusjan PM, Mizrahi R, Ginovart N, Graff A, Willeit M, Vitcu I et al (2006b). Validation of a method for automatic quantification of radioactivity in the globus pallidus in [11C]-(\+)-PHNO PET images. NeuroImage 31: T96.
49. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC Krishnan-Sarin S et al (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62: 649-659.
50. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33.
51. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J Abanades S et al (2012). Within-subject comparison of [(11)C] (\+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32: 127-136.
52. Smith RC, Lay CD (1974). State and trait anxiety: an annotated bibliography. Psychol Rep 34: 519-594.
53. Spinks R, Nopoulos P, Ward J, Fuller R, Magnotta VA, Andreasen NC (2005). Globus pallidus volume is related to symptom severity in neuroleptic naive patients with schizophrenia. Schizophr Res 73: 229-233.
54. Tiffany ST, Drobes DJ (1991). The development and initial validation of a questionnaire on smoking urges. Br J Addict 86: 1467-1476.
55. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N Domino EF (2002). Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse 45: 207-212.
56. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD Jenkinson M et al (2011). Imaging dopamine receptors in humans with [11C]-(\+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
57. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C et al (1999). Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291: 409-415.
58. Willeit M, Ginovart N, Graff A, Rusjan P, Mizrahi R, Seeman P et al (2006). In vivo competition of endogenous dopamine with the novel D2/3 receptor agonist-radioligand [11C]-(\+)-PHNO. Biol Psychiatr Meeting: Toronto, ON, Canada.
59. Williams JM, Gandhi KK, Lu SE, Kumar S, Steinberg ML, Cottler B et al (2011). Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug Alcohol Depend 118: 313-319.
60. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(\+)-4 propyl-3,4,4a,5,6,10b- hexahydro-2H-naphtho[1,2-b][1,4]oxazin 9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.